An NBC News article, “French authorities call for ban of Allergan textured breast implants” provides us with recent data on this issue. The number of BIA-ALCL diagnoses has gone from one per million to one per 2,832. The total number of cases now is 457 in the U.S. and approximately 700 worldwide. The number of deaths has risen from 9 to 16. The … [Read more...]
Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
There was an FDA CDRH General and Plastic Surgery Devices Advisory Committee Meeting held on March 25-26, 2019. The first day was focused in large part on Breast Implant Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL). This lymphoma cancer associated with breast implants is a rare type of blood cancer that is classified as a non-Hodgkin … [Read more...]
Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
In February 2019 the FDA announced that it has received a total of 660 medical device reports (MDRs) regarding breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), cases in the United States since 2010. This new total indicates an increase of about 246 new reports of breast implants lymphoma cancer cases in the past year. According … [Read more...]
Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
In December 2018 France’s National Agency for the Safety of Medicines and Health Products (ANSM) announced that Allergan textured breast implants can no longer be marketed in France and elsewhere in Europe. As regards what the FDA is doing on this developing medical device safety issue, we turn to this NBC News piece, “Allergan’s textured breast … [Read more...]
Several 2018 Breast Implant Lymphoma Cancer Lawsuits Already Filed
Background Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a type of non-Hodgkin's lymphoma, which is a cancer of the cells of the immune system. This rare T-cell lymphoma can develop as a result of breast implants, though the mechanism of injury is not fully understood at this time. However, based on current data from the … [Read more...]
FDA Provides Updated Number of Breast Implants Lymphoma Cancers
About BIA-ALCL The U.S. Food and Drug Administration (FDA) has been aware of the possible connection between breast implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) since 2011. This condition is a rare type of non-Hodgkin’s lymphoma, which is a cancer of the immune system, rather than a cancer of the breast … [Read more...]
New Data Released on Risk of Lymphoma Due to Breast Implants
Recent Study on BIA-ALCL RisksSince my last article on this topic, "What is the Risk of Death Due to Breast Implant-Associated Lymphoma?," additional information on the risk of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) has been released. The most recent study, titled "Breast Implants and the Risk of Anaplastic Large-Cell … [Read more...]
Breast Implant-Associated Lymphoma Diagnoses on the Rise
On October 18, 2017, the JAMA Surgery journal published an article titled "Breast Implant–Associated Anaplastic Large Cell Lymphoma A Systematic Review," in which they discuss the rate of occurrence of the condition. The article served as a review of 115 articles on the topic of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) … [Read more...]
What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
On August 23, 2017, the Aesthetic Surgery Journal distributed a press release concerning a recent study on the risk of death from Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). To provide some background information, BIA-ALCL is a rare non-Hodgkin lymphoma of T-cell origin that is typically found in the effusion fluid … [Read more...]
Treatments For Breast Implants Associated Lymphoma And Blood Cancer
In the August 2017 edition of the European Journal of Surgical Oncology(EJSO) we found this article, “Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent”. From the Abstract for this August 2017 EJSO article we get this new information about the … [Read more...]